FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Reeja Raj(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), César Núnêz(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Yuki Nishida(The University of Texas MD Anderson Cancer Center), Samanta Catueno(The University of Texas MD Anderson Cancer Center), Aziz Farhat(The University of Texas MD Anderson Cancer Center), Alexandra M. Stevens(Baylor College of Medicine)
Blood
September 19, 2025
Cited by 1


Related Papers